Anales de la RANM

34 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 S U P L E M E N T O I SIMPOSIO · JÓVENES INVESTIGADORES Libro de Abstracts An RANM. 2021;138(03).supl01: 34 - 54 Individuals with intra-abdominal origin sepsis (n=20), abdominal surgery individuals that had not developed sepsis (n=19), and a healthy control group (n=29) were recruited. The clinical ethics committee of the Clinical University Hospital Virgen de la Arrixaca (Murcia, Spain) approved this study and its procedures. NLRP3 inflammasome was stimulated in whole blood by LPS+ATP and Pyrin inflam- masome with LPS+TcdB. Flow cytometry was used to determine the formation of ASC specks formation in monocytes (CD14 + CD16 + CD15 - ) and ELISA to determine cytokine secretion. The evolution of clinical parameters, haematological features and plasma biochemistry parameters were evaluated. Figura 3. Panel A. Concentración de proteína C reactiva y procalcitonina en el plasma de los pacientes sépticos en los días 1, 3 y 5 tras el inicio de la sépsis, así como en el momento del alta hospitalaria. Las líneas discontinuas indican los valores estándar de dichas proteínas en la población sana. Panel B, C. Porcentaje de monocitos con oligómeros intracelulares de ASC después de la activación del inflammasoma NLRP3 con LPS (1 µg/ml, 2 h) y ATP (3 mM, 30 min) (Panel B) o tras la activación del inflamasoma Pirina con LPS (1 µg/ml, 2 h) y TcdB (1 µg/ml, 1 h) (Panel C) en ensayos de sangre completa procedentes de los pacientes sépticos sin inmunosupresión del inflamasoma NLRP3 (barras grises) o con inmunosupresión del inflamasoma NLRP3 (barras azules). Figure 3. Panel A. Concentrations of C-reactive protein and procalcitonin in plasma of septic patients at days 1, 3, and 5 during sepsis and at the moment of hospital discharge. Dotted lines represent standard threshold for CRP and PCT in healthy population. Panel B, C. Percentage of monocytes with intracellular ASC specks after NLRP3 inflammasome activa- tion by LPS (1 µg/ml, 2 h) and ATP (3 mM, 30 min) treatment (Panel B) or after Pyrin inflammasome activation by LPS (1 µg/ml, 2 h) and TcdB (1 µg/ml, 1 h) treatment (Panel C) in whole blood samples from septic patients non-immunocom- promised (grey bars) or immunocompromised for NLRP3 (blue bars).